In line with a Biden administration proposal, pharmaceutical giant Eli Lilly is cutting the price of its most commonly prescribed insulins by 70 percent and capping out-of-pocket costs at $35 or less per month.
"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change," said CEO David A. Ricks. "The aggressive price cuts we're announcing today should make a real difference for Americans with diabetes. Because these price cuts will take time for the insurance and pharmacy system to implement, we are taking the additional step to immediately cap out-of-pocket costs for patients who use Lilly insulin and are not covered by the recent Medicare Part D cap."
Here is a list of the drugs seeing price cuts, via Eli Lilly:
"We are driving for change in repricing older insulins, but we know that 7 out of 10 Americans don't use Lilly insulin," said Ricks. We are calling on policymakers, employers and others to join us in making insulin more affordable."
The company said it will launch a nationwide awareness campaign in the coming weeks to spread the word about its new lower costs.
Activists have long called for more affordable insulin, which even with insurance can place a financial burden on those in need. The American Diabetes Association has found that there are approximately $15 billion in excess costs for insulin in 2017.
President Donald Trump pulled a rabbit out of his trade war hat this week, announcing a trade deal with Japan putting 15% tariffs on most Japanese imports.
Nextdoor CEO Nirav Tolia shares how the neighborhood app's redesign aims to inform, connect, and protect communities with smarter features and local insight.
Tim Bohen dives into the 'Trump Trade,' renewed tariffs, waning uncertainty, corporate guidance, and what the Fed’s next move means for traders and markets.
Wall Street icon Peter Tuchman dives into Apex Trader Funding’s partnership with Wall Street Global Trading Academy and what it means for the next-gen trader.
Matthew Frankel, contributing analyst at The Motley Fool, discusses the recent SPAC resurgence, investor interest, and what the data says about their future.
Axios’ Neil Irwin unpacks the political clash as the White House explores legal pathways to dismiss Fed Chair Powell, threatening central bank independence.
